Abstract:ObjectiveTo analyze the clinical distribution and antimicrobial resistance of Acinetobacter baumannii (A.baumannii) from a hospital, so as to guide the rational use of antimicrobial agents and provide scientific basis for the prevention and control of healthcareassociated infection(HAI). MethodsDistribution and antimicrobial susceptibility testing results of A.baumannii isolated from patients between January 2011 and December 2013 were analyzed retrospectively. ResultsA total of 339 A. baumannii isolates were isolated within three years, 291 isolates (85.84%) were from sputum, followed by urine (n=29,8.55%）, secretion(n=12,3.54%) and blood (n=3, 0.89%). The main distribution departments were intensive care unit(ICU, n=149,43.95%), department of respiratory medicine (n=46,13.57%）, department of pediatrics (n=32,9.44%） and oncology (n=22, 6.49%）. The resistant rate of A.baumannii to tobramycin and imipenem were 11.11%49.47%, the resistant rates to the other antimicrobial agents were relatively high; antimicrobial resistant rate of 2012 and 2013 were obviously lower than 2011. ConclusionA. baumannii from this hospital are mainly from sputum specimens, and mainly distribute in ICU and department of respiratory medicine, antimicrobial resistant rate is high, but there is a decreasing tendency in recent years.